Onconetix, Inc. ONCO

SRX Global Inc has added an investment in Onconetix (ONCO) while liquidating two portfolio positions, Vistagen Therapeutics (VTGN) and Greenland Mines (GRML). The move comes as SRX anticipates the closing of Onconetix’s pending acquisition of Realbotix LLC. Realbotix has developed Vinci, an AI vision system embedded in robotic eyeballs that allows motion detection, user recognition, object/color identification, and emotion-reading micro-expressions to tailor dialogue via large language models. SRX argues Vinci is undervalued and could have defense applications, including drones and body cameras. The press release underscores SRX’s ongoing strategy to redeploy proceeds into high-conviction opportunities and notes forward-looking statements. Contacts for SRX and investor relations are provided. Investment in ONCO is tied to the Realbotix acquisition and could affect ONCO's strategic path if the deal closes.

Onconetix provides strategic bridge financing to Realbotix LLC to support pending acquisition. Bridge financing advances pending acquisition with likely significant effects on company trajectory.

Onconetix provides strategic bridge financing to Realbotix LLC in support of pending acquisition. Bridge financing for acquisition signals strategic move with moderate effect on operations and positioning.

Realbotix, Onconetix acquisition target, launches pilot with leading European telecommunications company to deploy humanoid robots in live presentations and events. Pilot by Realbotix adds moderate value and visibility to Onconetix acquisition target through new robotics deployment.

Onconetix, Inc. received a positive decision from the Nasdaq Hearings Panel on June 11, 2025, allowing continued listing on Nasdaq, contingent on compliance with specific listing rules. The company demonstrated compliance with the Periodic Filing Listing Rule on June 12, 2025, after filing its Form 10-Q. A 1-for-85 reverse stock split was executed on June 13, 2025, and Onconetix expects to meet the Bid Price Listing Rule by June 30, 2025. The decision to maintain Nasdaq listing and the reverse stock split are significant strategic moves that could impact investor sentiment and market performance.

Onco-Innovations completed a project with Kuano that used Kuano's quantum-based platform to generate insights for optimizing PNKP Inhibitor Technology. Project completion supplies quantum-derived optimization insights for PNKP inhibitor technology.

Onconetix reports Q1 2026 progress at Proteomedix AG, including two new peer-reviewed publications and initiation of a U.S. validation study. Peer-reviewed publications and U.S. validation study initiation represent major advancements in diagnostic validation and market positioning.

Onconetix, Inc. (ONCO) strengthens executive leadership by appointing Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development. Appointing specialized CMO and R&D chief bolsters clinical trial execution and innovation pipeline in oncology.

Onconetix highlights Realbotix's launch of the Vinci AI Vision System, marked by delivery of the first Vinci-equipped humanoid robot to Ericsson. Launch of Vinci AI and first delivery to Ericsson represents a major product milestone enhancing Onconetix's robotics positioning.

Onco-Innovations executes engagement agreement with RDI Partners and establishes Onco-Innovations AU Pty. Ltd. to advance Australian Phase I strategy. Strategic partnership and Australian subsidiary formation support Phase I clinical expansion, offering moderate potential to enhance pipeline progress and market positioning.

Onconetix, Inc. (ONCO) appointed David White as Chief Executive Officer and Sammy Dorf as a member of the Board of Directors. New CEO and board member appointments signal major leadership changes that could reshape strategic direction and boost investor sentiment.

Onconetix spotlights Realbotix's key role in Ericsson's world-first 6G trial demonstration. Realbotix's involvement in Ericsson's pioneering 6G trial signals major strategic advancements in telecom and robotics for Onconetix.

Onconetix, Inc. announced the validation of its prostate cancer test, Proclarix, in a Danish cohort. The study demonstrated Proclarix's effectiveness in distinguishing between aggressive and non-aggressive prostate cancer, potentially improving patient management and treatment decisions. This validation is expected to enhance the test's credibility and market acceptance, paving the way for broader clinical use. Validation of Proclarix in a significant cohort is likely to enhance its market position and influence future sales.

Onconetix, Inc. has announced its acquisition of Realbotix LLC, a USA-based company specializing in AI-powered humanoid robotics. This strategic move aims to enhance Onconetix's technological capabilities and expand its product offerings in the rapidly evolving field of robotics and artificial intelligence. The acquisition is expected to position Onconetix favorably within the market, leveraging Realbotix's innovations to drive future growth. The acquisition of Realbotix is a significant strategic move that could enhance Onconetix's competitive positioning and market presence.

Realbotix, Inc. has announced the sale of its subsidiary, Realbotix, LLC, to Onconetix, Inc. This strategic move is expected to enhance Onconetix's portfolio and operational capabilities in the biotechnology sector. The acquisition may moderately influence Onconetix's competitive positioning and operational scope in the biotech industry.

Onconetix, Inc. (ONCO) has announced a financing initiative through a private placement and a debt settlement strategy. This move aims to strengthen the company's financial position and support its ongoing operations and growth plans. The details of the financing arrangement and the implications for the company's future were not disclosed. The financing through private placement and debt settlement is expected to moderately influence Onconetix's financial performance and operational capabilities.

Onconetix, Inc. has completed a $12.9 million private placement of Series D preferred stock and warrants. The company has also terminated its merger agreement with Ocuvex, Inc. and settled an $8.8 million debt with Veru, Inc. The financing and debt settlement are significant strategic moves that could alter the company's financial stability and market positioning.

Onconetix, Inc. announced that its subsidiary, Proteomedix, has licensed manufacturing intellectual property to Immunovia. This agreement allows Immunovia to independently produce key reagents for its pancreatic cancer test, PancreaSureTM. The licensing agreement may enhance Immunovia's operational capabilities, potentially benefiting Onconetix's market position.

Onconetix, Inc. (ONCO) has been identified as one of the most active stocks in the market, indicating heightened trading activity and investor interest. This surge in activity may reflect recent developments or market sentiment surrounding the company, potentially influencing its stock performance and investor perceptions. Increased trading activity suggests a moderate influence on market sentiment and potential financial performance.

Onconetix, Inc. and Ocuvex Therapeutics have entered into a definitive merger agreement, where Onconetix will acquire all equity interests of Ocuvex. Ocuvex equity holders will receive newly-issued shares of Onconetix common stock, representing 90% of the combined company, while Onconetix shareholders will retain 10%. The merger aims to enhance Onconetix's portfolio with Ocuvex's ophthalmic assets and is expected to close in the fourth quarter of 2025, pending regulatory and stockholder approvals. The merger significantly enhances Onconetix's product pipeline and market position in the ophthalmic sector.

Onconetix, Inc. has announced a 1-for-85 reverse stock split, which is aimed at increasing the per-share price of its common stock. The decision was made during a special meeting of stockholders, where shareholders approved the reverse split. This move is intended to help the company meet the minimum bid price requirement for continued listing on the Nasdaq stock exchange. The reverse stock split may influence market perception and compliance with listing requirements, but its overall impact on the company's long-term trajectory is expected to be limited.

Onconetix (ONCO) received a delisting notice from Nasdaq due to its failure to file the Quarterly Report for Q1 2025 and the Annual Report for FY24, violating Nasdaq's listing requirements. The company also faced a minimum bid price violation, with shares closing at 10c or less for ten consecutive trading days. On April 14, Nasdaq notified the company of the potential delisting, but Onconetix requested a hearing, which is scheduled for May 27, to stay the suspension of trading. The company aims to file the necessary reports promptly to regain compliance. The delisting notice and the company's efforts to regain compliance could significantly impact investor sentiment and market performance.

Onconetix, Inc. received a delisting notice from Nasdaq due to its failure to file the Quarterly Report on Form 10-Q for Q1 2025, violating Nasdaq Listing Rule 5250(c)(1). This follows a previous notice regarding non-compliance with the timely filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. Additionally, the company faced a delisting threat due to its common stock closing bid price falling below $1.00. Onconetix has requested a hearing to appeal the delisting and intends to file the necessary reports to regain compliance. The company is facing multiple compliance issues with Nasdaq that could significantly impact its market performance and investor sentiment.

Onconetix, Inc. received a Staff delisting letter from Nasdaq on April 24, 2025, due to its failure to file the Annual Report on Form 10-K for the fiscal year ended December 30, 2024, violating Nasdaq Listing Rule 5250(c)(1). The company is already addressing a previous delisting notice related to the Minimum Bid Price Rule and has until May 1, 2025, to request a stay of suspension. Onconetix plans to file the Form 10-K promptly to regain compliance. The delisting notices and compliance issues could significantly impact Onconetix's market performance and investor sentiment.

Onconetix, Inc. has signed a Non-Binding Letter of Intent with Ocuvex Therapeutics, Inc. for a potential business combination. This merger aims to expand Onconetix's reach beyond oncology by incorporating Ocuvex's ophthalmic therapeutic assets. Following the transaction, Ocuvex equity holders will own approximately 90% of Onconetix. The deal is contingent on due diligence, financing, and regulatory approvals, with no guarantee of completion. The proposed merger with Ocuvex could significantly enhance Onconetix's product portfolio and market position in the ophthalmic sector.

Onconetix, Inc. announced successful clinical validation of its prostate cancer test Proclarix® at the 2025 EAU congress, demonstrating strong performance in a Danish cohort. The test showed a 5% probability of clinically significant cancer in patients with elevated PSA levels, outperforming existing diagnostic tools. Proclarix® avoided 22% of unnecessary biopsies and confirmed a sensitivity of 96% in a larger population. The test is CE-certified and indicated for patients with elevated PSA levels. Onconetix, which recently acquired Proteomedix, plans to market Proclarix® in the U.S. as a lab-developed test. Successful validation of Proclarix® could significantly enhance Onconetix's market position and investor sentiment.

Onconetix, Inc. announced that new clinical data for its prostate cancer test, Proclarix, has been accepted for presentation at the 2025 European Association of Urology Congress. This acceptance highlights the test's innovative approach and potential impact on prostate cancer diagnosis and management. The acceptance of new clinical data for Proclarix at a significant medical congress is likely to enhance the company's market position and investor sentiment.

Onconetix, Inc. announced a private placement of Series C Preferred Stock and Warrants, raising $2.0 million, and established a $25 million equity line of credit. The private placement and equity line of credit are significant financial moves that could impact the company's future growth and operations.

Onconetix, Inc. announced a private placement of Series C Preferred Stock and Warrants, raising $2.0 million, and established a $25 million equity line of credit. The company plans to use the proceeds for working capital and general corporate purposes. The private placement and equity line of credit are significant financial moves that could impact the company's future operations and growth potential.

Onconetix, Inc. announced a 1-for-40 reverse stock split and the results of the annual meeting of stockholders, including the approval of various proposals. The reverse stock split and approved proposals are expected to have a significant impact on Onconetix's future financial performance and market positioning.